Pan-cancer treatment response monitoring

SeekInClarity^® is the first-in-class blood-based pan-cancer pan-indication treatment response monitoring test, which uses a cutting edge multivariable molecular tumor burden (MTB) algorithm. Molecular response index (MRI) model maps the panoramic cancer genome by shallow whole genome squencing (sWGS) data, evaluates the copy number aberration (CNA)，fragment size (FS) and 7 plasma protein markers, to predict tumor burden and therapeutic efficacy of the late-stage cancer patients during treatment including chemotherapy, target therapy and immunotherapy or combination therapies.

Indicated subjects: Late-stage cancer patients
Sample requirement: 10ml peripheral blood

TAT：10 working days

Result readout: MTB (molecular tumor burden)
Sampling time: